These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
100 related articles for article (PubMed ID: 16760455)
1. Tenofovir DF and emtricitabine vs. zidovudine and lamivudine. Laessig KA; Lewis LL; Hammerstrom TS N Engl J Med; 2006 Jun; 354(23):2506-8; author reply 2506-8. PubMed ID: 16760455 [No Abstract] [Full Text] [Related]
2. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. Gallant JE; DeJesus E; Arribas JR; Pozniak AL; Gazzard B; Campo RE; Lu B; McColl D; Chuck S; Enejosa J; Toole JJ; Cheng AK; N Engl J Med; 2006 Jan; 354(3):251-60. PubMed ID: 16421366 [TBL] [Abstract][Full Text] [Related]
3. Tenofovir DF plus lamivudine or emtricitabine for nonoccupational postexposure prophylaxis (NPEP) in a Boston Community Health Center. Mayer KH; Mimiaga MJ; Cohen D; Grasso C; Bill R; Van Derwarker R; Fisher A J Acquir Immune Defic Syndr; 2008 Apr; 47(4):494-9. PubMed ID: 18176318 [TBL] [Abstract][Full Text] [Related]
4. Tenofovir DF and emtricitabine vs. zidovudine and lamivudine. Jenny-Avital ER N Engl J Med; 2006 Jun; 354(23):2506-8; author reply 2506-8. PubMed ID: 16764056 [No Abstract] [Full Text] [Related]
5. Abacavir/3TC vs. tenofovir/FTC: interim results from ACTG 5202. Albrecht H AIDS Clin Care; 2008 Apr; 20(4):28. PubMed ID: 19271262 [No Abstract] [Full Text] [Related]
6. Cost-effectiveness analysis of emtricitabine/tenofovir versus lamivudine/zidovudine, in combination with efavirenz, in antiretroviral-naive, HIV-1-infected patients. Sánchez-de la Rosa R; Herrera L; Moreno S Clin Ther; 2008 Feb; 30(2):372-81. PubMed ID: 18343275 [TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic interactions between lersivirine and zidovudine, tenofovir disoproxil fumarate/emtricitabine and abacavir/lamivudine. Vourvahis M; Davis J; Langdon G; Layton G; Fang J; Choo HW; Hansson AG; Tawadrous M Antivir Ther; 2013; 18(6):745-54. PubMed ID: 23558061 [TBL] [Abstract][Full Text] [Related]
8. Preexposure prophylaxis for HIV--where do we go from here? Cohen MS; Baden LR N Engl J Med; 2012 Aug; 367(5):459-61. PubMed ID: 22784041 [No Abstract] [Full Text] [Related]
9. Recent availability of two novel, fixed formulations of antiretroviral nucleoside analogues: a 12-month prospective, open-label survey of their practical use and therapeutic perspectives in antiretroviral-naive and -experienced patients. Manfredi R; Calza L AIDS Patient Care STDS; 2008 Apr; 22(4):279-90. PubMed ID: 18290748 [TBL] [Abstract][Full Text] [Related]
10. Meeting notes from ICAAC. Tenofovir + emtricitabine vs. AZT + 3TC. Feinberg J AIDS Clin Care; 2005 Jan; 17(1):7. PubMed ID: 15717373 [No Abstract] [Full Text] [Related]
12. Integrating HIV prevention into practice. Mathers BM; Cooper DA JAMA; 2014 Jul 23-30; 312(4):349-50. PubMed ID: 25038352 [No Abstract] [Full Text] [Related]
13. Antiretrovirals for HIV Exposure Prophylaxis. Nikolopoulos G; Tsiodras S; Bonovas S; Hatzakis A Curr Med Chem; 2012; 19(35):5924-39. PubMed ID: 22963555 [TBL] [Abstract][Full Text] [Related]
14. The ART of preventing HIV. Nat Med; 2011 Jan; 17(1):46-7. PubMed ID: 21217682 [No Abstract] [Full Text] [Related]
15. Efficacy of pegylated interferon plus ribavirin treatment in HIV/hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone. Mira JA; López-Cortés LF; Barreiro P; Tural C; Torres-Tortosa M; de Los Santos Gil I; Martín-Rico P; Ríos-Villegas MJ; Hernández-Burruezo JJ; Merino D; López-Ruz MA; Rivero A; Muñoz L; González-Serrano M; Collado A; Macías J; Viciana P; Soriano V; Pineda JA J Antimicrob Chemother; 2008 Dec; 62(6):1365-73. PubMed ID: 18854330 [TBL] [Abstract][Full Text] [Related]
16. Low rate of treatment failure on antiretroviral therapy with tenofovir, lamivudine and zidovudine. Mauss S; Milinkovic A; Hoffmann C; Holm S; Berger F; Martínez E; Kuhlmann B; Gatell J; Schmutz G AIDS; 2005 Jan; 19(1):101-2. PubMed ID: 15627042 [No Abstract] [Full Text] [Related]
17. Rapid improvement in fasting lipids and hepatic toxicity after switching from didanosine/lamivudine to tenofovir/emtricitabine in patients with toxicity attributable to didanosine. Palacios R; Rivero A; Santos I; Ríos MJ; Castaño M; del Arco A; Santos González J; HIV Clin Trials; 2010; 11(2):118-20. PubMed ID: 20542848 [No Abstract] [Full Text] [Related]
18. A comparison of measured and estimated glomerular filtration rate in successfully treated HIV-patients with preserved renal function. Vrouenraets SM; Fux CA; Wit FW; Garcia EF; Brinkman K; Hoek FJ; van Straalen JP; Furrer H; Krediet RT; Reiss P; Clin Nephrol; 2012 Apr; 77(4):311-20. PubMed ID: 22445475 [TBL] [Abstract][Full Text] [Related]
19. Anti-HIV agents. Low rate of early virologic failure seen with a combination of Trizivir and tenofovir. TreatmentUpdate; 2004 Mar; 16(2):2-3. PubMed ID: 17219666 [No Abstract] [Full Text] [Related]